Generic drugmaker Hikma pledges $1bn in US investment
pharmaphorum
JUNE 30, 2025
With tariffs looming, Indian drugmaker Hikma has said it will spend $1bn to expand its manufacturing and R&D operations in the US by 2030.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
pharmaphorum
JUNE 30, 2025
With tariffs looming, Indian drugmaker Hikma has said it will spend $1bn to expand its manufacturing and R&D operations in the US by 2030.
Pharmaceutical Technology
JULY 23, 2025
AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D). It will also support our ambition to reach $80bn in revenue by 2030.” Credit: grandbrothers/Shutterstock.com.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PQA
JULY 18, 2025
PQA is developing its next strategic plan, Blueprint PQA 2030, which will guide the organization’s work from 2026 through 2030. As with PQA’s 2021 summit, this year’s summit will leverage PQA members’ expertise to inform the strategies and tactics that will be key to success through 2030. Welcome to Five For Friday!
STAT
APRIL 29, 2025
The companies also see compounders as a threat to their obesity drug sales, which are estimated to balloon to $100 billion a year by 2030. (The FDA has received more than 700 adverse event reports tied to compounded GLP-1s, but it’s not clear if the events were caused by the drugs.)
European Pharmaceutical Review
JULY 4, 2025
Only a few big pharma companies are positioned to grow revenue sustainably through 2030, stated GlobalData. As such, the US market is expected to lose over $230 billion over the next five years. Which blockbuster drugs could be impacted in the next pharmaceutical patent cliff?
PharmaVoice
JULY 21, 2025
EY data underscores the urgency of this marketing transformation to mitigate potential revenue losses estimated at $230 billion by 2030. “A lot of companies are trying now to figure out how to use digital assets better, but its a very slow adoption in the marketplace,” Schur said.
Pharmacy Times
AUGUST 5, 2025
of US adults received a vaccine, far short of the Healthy People 2030 target of 70%. Healthy People 2030. Meet Communities Where They Are Although influenza vaccines are widely available, vaccination rates remain below national goals. During the 2023-2024 influenza season, only 44.9% Accessed June 10, 2025. September 20, 2024.
Pharmacy Times
JUNE 18, 2025
The Healthy People 2030 initiative addresses structural health care inequalities and implements programs to ameliorate SDOH. Healthy People 2030. Each unique set of economic, educational, social, and environmental circumstances significantly affects their quality of life and health. REFERENCES 1. Social determinants of health.
European Pharmaceutical Review
APRIL 10, 2025
In the EU, a joint PFAS Restriction Proposal under REACH was submitted, aiming for a full ban by 2028/2030. The PFAS regulatory challenge As a result, in the EU, a joint PFAS Restriction Proposal under REACH was submitted in 2023, aiming for a full ban on all PFAS by 2028/2030. There is worldwide concern around the use of PFAS.
Pharmacy Times
JUNE 9, 2025
2019;380:2020-2030. Global Initiative for Asthma. Accessed June 9, 2025. Beasley R, Holliday M, Reddell HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med.
PharmaVoice
JUNE 27, 2025
Now, the WHO’s aggressive goal to “ end HIV/AIDS ” by 2030 could be hampered by dramatic reductions in U.S. million Americans are infected with HIV, but the disease disproportionately impacts people in sub-Saharan Africa. Daiichi Sankyo’s ADC programs also include candidates it’s developing with Merck & Co.
European Pharmaceutical Review
AUGUST 13, 2025
Among them are Johnson & Johnson, which has earmarked $55 billion over the next four years; AstraZeneca plans to put in $50 billion by 2030; Roche will also spend $50 billion over the next five years; and there are smaller investment promises from UCB ($5 billion) and Merck & Co ($3.5
PharmTech
JULY 4, 2025
Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report Susan Haigney June 30th 2025 Article The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.
European Pharmaceutical Review
JUNE 27, 2025
This includes initiatives such as ATMP 2030 led out of Sweden. Regional hubs, specialising in CGT manufacturing, process and product development and training to increase specialised workforces within the region have also been established, and thrive.
PQA
AUGUST 1, 2025
This year’s summit will focus on Blueprint PQA 2030, PQA’s strategic plan that is in development and will guide the organization’s work from 2026 through 2030. Summit Focused on Blueprint PQA 2030 PQA is developing its next strategic plan, Blueprint PQA 2030, which will guide the organization’s work from 2026 through 2030.
Pharmacy Times
JUNE 19, 2025
With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings. 2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025.
Pharmacy Times
JUNE 19, 2025
million deaths in 2019, and this is predicted to increase to approximately 23 million annual deaths by 2030. A steady increase in CVD-related deaths resulted in approximately 18.6 1 CVDs are disorders affecting the heart and blood vessels.
PharmaVoice
JULY 24, 2025
All told, AstraZeneca aims to boost its total revenue from the $54 billion -mark it hit in 2024 to over $80 billion by 2030 — half of which it expects to be generated in the U.S., The American market for drugs also plays a starring role in the company’s broader ambitions. the company said.
Pharmacy Times
JULY 21, 2025
Furthermore, by 2030, the proportion of aging among PLWH are set to increase across geographic regions and gender. This trend is similar for patients contracting HIV, according to Wong; currently, 40 million individuals live with HIV worldwide, and among these, almost 10 million are aged 50 years or older.
Pharmaceutical Technology
JULY 4, 2025
Robert Barrie July 4, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Only 4% of global drugs sales in 2030 will have patent protection. A recent report by GlobalData projects that the share of global drug sales under patent protection will decline by 2030. LanKS via Shutterstock.
Pharmaceutical Commerce
JULY 22, 2025
AstraZeneca will be investing $50 billion in the United States by the year 2030. billion announced in November of last year, 1 it will be investing $50 billion in the United States by the year 2030. billion announced in November of last year, 1 it will be investing $50 billion in the United States by the year 2030.
European Pharmaceutical Review
JUNE 24, 2025
We are particularly encouraged by the Government’s ambitious goal to make the UK the leading life sciences economy in Europe by 2030, and the third most important globally by 2035.
Pharmaceutical Commerce
JUNE 23, 2025
Image Credit: Adobe Stock Images/StockMediaLabs.com Evaluate, who provides market insights for the pharma industry, has unveiled its “2025 World Preview Report,” which offers insights for the global pharmaceutical market through the year 2030. They are also expected make up close to 9% of all Rx drug sales by the end of the decade.
Pharmaceutical Commerce
JULY 31, 2025
June 28 - Hikma Pharmaceuticals USA announces that it will be financially committing $1 billion by the year 2030 to further grow its US manufacturing and R&D capabilities. Hikma Commits $1 Billion to Boost US Drug Manufacturing and R&D Services by 2030. UCB to Invest $5 Billion into US Production Plant. Pharmaceutical Commerce.
PharmD Live
JUNE 2, 2025
By 2025, over 71 million Americans (26% of the population) are expected to use RPM services, with the US market projected to double to $29+ billion by 2030. billion by 2030 with 12.8% RPM’s Booming Promise and Its Perils Remote patient monitoring (RPM) is not just a trend but a core pillar of modern US healthcare. OEI-02-23-00260).
PharmTech
JULY 1, 2025
Recent Videos Related Content Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report Susan Haigney June 30th 2025 Article The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.
PharmTech
JUNE 10, 2025
The global biopharma industry is expected to increase at a compound annual growth rate of 8.97% from 2025 to 2030; this growth is suspected to result from a demand for targeted therapies, new alliances, and increased innovation (1).
Drug Topics
JUNE 12, 2025
1 "The label expansion for Mavyret, coupled with the implementation of test and treat models of care, serve as tools to support the public health community in treating more patients and bringing us closer to achieving the global 2030 elimination goal."
Pharmaceutical Commerce
JULY 29, 2025
The tariff is meant to encourage pharma manufacturers to reshore their production back to the United States, which has been in the works for many players, including AstraZeneca, who plans to invest $50 billion by 2030 in US-based drug manufacturing and R&D, marking its largest single manufacturing investment globally.
Pharmaceutical Technology
JULY 24, 2025
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices?
Pharmaceutical Technology
JULY 28, 2025
In a Gilead statement, Université Paris Cité infectious diseases professor Jean-Michel Molina said: “These positive opinions from the CHMP are an important step toward a new HIV prevention option that could help meet the diverse needs of people across Europe and aim at helping end new HIV infections by the EU target of 2030.
Pharmaceutical Technology
JULY 8, 2025
Chugai president and CEO Dr Osamu Okuda stated: “We believe that open innovation with external partners, including leading global players, is extremely important for achieving global first-class drug discovery outlined in our growth strategy toward 2030, TOP I 2030. “By
Pharma Marketing Network
APRIL 20, 2025
With proper antiretroviral treatment, individuals can live 2030 years after an AIDS diagnosis. With continued advocacy, education, and innovation, the goal of turning AIDS into a manageable chronic condition worldwide is within reach. FAQs What is the average survival rate after an AIDS diagnosis? Can AIDS be cured completely?
Pharmaceutical Technology
JULY 24, 2025
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices?
Pharmaceutical Technology
JUNE 18, 2025
The goal is to take annual bilateral trade between the two nations to $500 billion by 2030 from the current $190 billion. Leyla Hasanzadeh June 18, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Tech transfer for manufacturing purposes in India will be difficult if Trump imposes import duties on pharmaceuticals.
Pharmaceutical Technology
JULY 21, 2025
Both companies plan to further innovate partnerships within the medical industry’s digital landscape, aiming to improve patient outcomes and also contribute towards achieving national Healthy China 2030 objectives.
Pharma Times
JULY 8, 2025
By 2030, an estimated 25 million patients in the US and Europe will be on FXa DOACs for long-term conditions including atrial fibrillation and deep vein thrombosis. Crucially, the treatment does not increase thrombotic risk, a key concern in managing emergency bleeding scenarios.
PharmTech
JUNE 30, 2025
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com Hikma Pharmaceuticals USA announced on June 28, 2025 that it is investing $1 billion by 2030 to expand its generic-drug R&D and manufacturing capabilities in its Ohio and New Jersey, United States, facilities.
Pharmaceutical Commerce
JULY 10, 2025
Hikma Commits $1 Billion to Boost US Drug Manufacturing and R&D Services by 2030 Nicholas Saraceno, Editor July 3rd 2025 Article The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient needs through domestic innovation and capacity.
Pharmaceutical Commerce
JULY 23, 2025
Companies such as AstraZeneca are committing massive investments, including $50 billion in US manufacturing and R&D by 2030, to strengthen domestic production and mitigate tariff impacts. It will also support our ambition to reach $80 billion in revenue by 2030. Trump Says Pharma Industry Should Expect Tariffs by Aug. Saraceno N.
Pharmaceutical Technology
JULY 24, 2025
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices?
Pharmaceutical Technology
AUGUST 5, 2025
The Gates Foundation has announced an investment of $2.5bn to 2030, dedicated to expediting R&D with a focus on improving women's health.
Pharmaceutical Commerce
JULY 3, 2025
The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient needs through domestic innovation and capacity.
Pharmaceutical Technology
JULY 2, 2025
The projected growth of the cell and gene therapy market GlobalData estimates that the cell and gene therapy market will achieve global sales of $76.03bn by 2030, up from $5.88bn in 2023, with a compound annual growth rate (CAGR) of 44% over the seven years analysed. of the global market, valued at $39.3bn. of the global sales total.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content